Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.
Saved in:
| Title: | Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial. |
|---|---|
| Authors: | Ngoi NYL; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore., Lee JY; Department of Obstetrics and Gynecology, Yonsei Cancer Center and Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea., Lim D; Department of Pathology, National University Hospital, Singapore., Thian YL; Department of Diagnostic Imaging, National University Hospital, Singapore., Lim YW; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore., Chan JJ; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., Chay WY; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., Zhang Z; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., Gopinathan A; Department of Diagnostic Imaging, National University Hospital, Singapore., Lim SE; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore., Low J; Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, National University Hospital, Singapore, Singapore., Ng J; Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, National University Hospital, Singapore, Singapore., Tong P; Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, National University Hospital, Singapore, Singapore., Lee YJ; Department of Obstetrics and Gynecology, Yonsei Cancer Center and Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea., Park J; Department of Obstetrics and Gynecology, Soonchunhyang University College of Medicine, Bucheon, South Korea., Kim JW; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea., Tan TZ; Cancer Science Institute of Singapore, National University of Singapore, Singapore., Zhu J; Saw Swee Hock School of Public Health, National University of Singapore, Singapore., Tai BC; Saw Swee Hock School of Public Health, National University of Singapore, Singapore., Choi CH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Kim BG; Chung-Ang University Gwang-myeong Hospital, Gwang-myeong, South Korea., Tan DSP; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: david_sp_tan@nuhs.edu.sg. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2026 Feb; Vol. 27 (2), pp. 201-211. Date of Electronic Publication: 2026 Jan 15. |
| Publication Type: | Journal Article; Multicenter Study; Clinical Trial, Phase II |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
